Literature DB >> 14560042

The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cells.

Na Qiao1, Denis Reynaud, Peter Demin, Perry V Halushka, Cecil R Pace-Asciak.   

Abstract

The hepoxilin analog PBT-3 [10(S)-hydroxy-11,12-cyclopropyleicosa-5Z,8Z,14Z-trienoic acid methyl ester] was previously shown to inhibit the aggregation of human platelets and to antagonize the binding of the thromboxane receptor agonist I-BOP [[1S-[1alpha,2alpha (Z),3beta(1E,3S*),4alpha]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid] in human platelets (Pace-Asciak et al., 2002). We show herein that PBT-3 inhibits, to different degrees, binding of the TP receptor antagonist [3H]SQ 29,548 [[1S-[1alpha,2alpha (Z),3alpha,4alpha]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2. 1]hept-2-yl]-5-heptenoic acid], to the TP receptor isoforms in TPalpha- and TPbeta-transfected COS-7 cells. These isoforms possess a different tail length, the alpha being shorter than the beta isoform. In contrast, SQ 29,548 shows no selection for the two TP isoforms. The IC50 value for PBT-3 = 2.0 +/- 0.3 x 10-7 M was observed for TPalpha, whereas this was one-sixth less active on the TPbeta isoform (IC50 = 1.2 +/- 0.2 x 10-6 M), suggesting selectivity for the TPalpha isoform. To investigate whether the tail contributes to the difference in competition binding by PBT-3, we investigated the tailless TP isoform expressed in transfected COS-7 cells. Its IC50 was similar to that of the TPalpha isoform. In additional studies, we investigated the effect of PBT-3 on the collagen and I-BOP evoked intracellular calcium release and on the collagen and I-BOP evoked phosphorylation of pleckstrin. PBT-3 blocked both pathways further demonstrating its TP receptor antagonist activity. These results demonstrate that the action of PBT-3 in inhibiting platelet aggregation is mediated via inhibition of the TPalpha isoform of the thromboxane receptor and that the tail may play an important role in recognition of this TP receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14560042     DOI: 10.1124/jpet.103.056705

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Novel eicosanoid pathways: the discovery of prostacyclin/6-keto prostaglandin F1alpha and the hepoxilins.

Authors:  Cecil R Pace-Asciak
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

Review 2.  The hepoxilins and some analogues: a review of their biology.

Authors:  Cecil R Pace-Asciak
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

Review 3.  Antiplatelet therapies for the treatment of cardiovascular disease.

Authors:  Alan D Michelson
Journal:  Nat Rev Drug Discov       Date:  2010-02       Impact factor: 84.694

4.  Vascular hepoxilin and trioxilins mediate vasorelaxation through TP receptor inhibition in mouse arteries.

Authors:  L Siangjong; D H Goldman; T Kriska; K M Gauthier; E M Smyth; N Puli; G Kumar; J R Falck; W B Campbell
Journal:  Acta Physiol (Oxf)       Date:  2016-01-04       Impact factor: 6.311

Review 5.  The Role and Regulation of Thromboxane A2 Signaling in Cancer-Trojan Horses and Misdirection.

Authors:  Anthony W Ashton; Yunjia Zhang; Rosanna Cazzolli; Kenneth V Honn
Journal:  Molecules       Date:  2022-09-22       Impact factor: 4.927

Review 6.  A review of non-prostanoid, eicosanoid receptors: expression, characterization, regulation, and mechanism of action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2021-06-26       Impact factor: 5.782

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.